Neurostatus-UHB AG (Ltd.)

Based in Basel, Switzerland, as part of the University Hospital Basel (UHB), Neurostatus-UHB Ltd. is the leading provider of expertise in the standardized neurological assessment of clinical symptoms in Multiple Sclerosis (MS) and related neuro-immunological diseases, the Neurostatus-EDSS. Further, Neurostatus-UHB develops digital solutions for the capture, quantification and documentation of clinical symptoms and has expertise in software validation.

Neurostatus-UHB Ltd. provides services for randomized controlled  trials (RCTs), academic studies and clinical routine. These include:

• Licenses for the paper & pen version of the Neurostatus-EDSS 
• Licenses for the digital version of the Neurostatus-EDSS, the Neurostatus-eEDSS. The Neurostatus-eEDSS provides an algorithm-based consistency check and automated feedback on the Neurostatus-EDSS assessments data. Assessments labelled as inconsistent are reviewed by our team of EDSS experts who support the rater (i.e. user) in their resolution. The eEDSS is currently being provided by four external electronic clinical outcome assessment (eCOA) companies under non-exclusive licenses, and through our in-house digital solutions, depending on the studies’ requirements and complexities. 
• An online certification process (the Neurostatus-eTest) for Neurostatus-(e)EDSS raters, as an element of quality control for Neurostatus-(e)EDSS data
• Training, both face-to-face and online, and the provision of training and scoring materials 

All further information about Neurostatus-UHB can be found on the company website.  

• Numbers 1 to 5a represent the automated real-time feedback; 
• Numbers 5b to 9b the expert interaction with on-site raters via eCOA platforms.
   

The Neurostatus-EDSS scale was first introduced in the early 1990s by Professor Ludwig Kappos and his team at the University Hospital Basel, as part of an MS research group. 

Since then it has become the “gold-standard” for use during phase III RCTs in MS, including most noteworthy for those trials that led to the approval of the currently used disease modifying treatments (DMTs). 

In 2009, led by the current CEO, PD Dr. med. Marcus D’Souza, the Neurostatus-eEDSS was introduced. Along with the COO, Evy Fricker, and their team, they are currently supporting more than 100 active MS and related disorders studies, more than 30 of which are using the digital eEDSS. 

In November 2021, the initial research group was incorporated as a limited company wholly owned by the University Hospital Basel.